特一藥業(002728.SZ):164個產品品規納入新版醫保目錄
格隆匯8月26日丨特一藥業(002728.SZ)公佈,2019年8月20日,國家醫保局和人力資源社會保障部發布《關於印發〈國家基本醫療保險、工傷保險和生育保險藥品目錄>的通知》(醫保發〔2019〕46號)。公司及全資子公司海南海力、新寧製藥本次納入《醫保目錄2019年版》的藥品有164個產品品規,其中生產的有42個品規,未生產的有122個品規。
本次調入《醫保目錄》的藥品中,新增調入的有3個品規(其中2個在產,包括血塞通分散片和鋁碳酸鎂咀嚼片),調出《醫保目錄》藥品有11個品規(其中2個在產,9個不在產);調整醫保分類的有4個品規(其中3個由“乙類”調整為“甲類”,1個由“甲類”調整為“乙類”)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.